publication date: Nov. 13, 2020
Issue 43 - Nov. 13, 2020
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • News Analysis

    Joe Biden has an unparalleled grasp of the science and politics of cancer

    For the first time in U.S. history, the White House will soon be occupied by a president who has demonstrated a deep understanding of cancer research.

  • Guest Editorial

    A Biden-Harris administration will help sustain our momentum in the fight against cancer

    The recent historic election of President-elect Joe Biden and Vice President-elect Kamala Harris provides an exciting opportunity for the cancer research and medical science communities during the next four years to dramatically improve the health of our nation and the world.

  • An Appreciation

    David A. Ahlquist, pioneer of cancer screening, dies at 69

    With unwavering positivity and unquenchable curiosity, David A. Ahlquist, MD, turned complex challenges into addressable opportunities, and audacious ideas into achievable realities.

  • In Brief

    • Abraham Chachoua named director of Perlmutter Cancer Center’s Lung Cancer Center
    • CWRU and UH Researchers receive $5 million from NCI to investigate relationships between HIV and lung cancer in East Africa
    • John Turchi receives $2.9 million from NCI to improve effectiveness of lung cancer radiation therapy
    • SWOG and The Hope Foundation award two grants designed to give military veterans better access to cancer clinical trials
    • The US Oncology Network enrolls 100,000th patient in the Oncology Care Model
  • TCCL Logo

  • Trials & Tribulations

    #BCSM: Breast cancer social media hashtag gives voice to a community

    When they decided to launch a weekly breast cancer chat on Twitter, all breast cancer survivors and advocates Alicia Staley and Jody Schoger had was a hashtag and a dream.

  • Clinical Roundup

    • Keytruda + Lenvima meet PFS primary endpoint in advanced RCC
    • KEYNOTE-695 study: Tavo + Keytruda demonstrate 30% ORR in anti-PD-1 checkpoint refractory metastatic melanoma
    • State-level lung cancer screening rates are not aligned with lung cancer burden in the U.S.
    • Diagnostic imaging may increase risk of testicular cancer
    • JNCCN study evaluates cost-effectiveness of olaparib for metastatic pancreatic cancer
    • Research detects hormone-upregulated lncRNA within the lymphocyte-specific protein tyrosine kinase discovered in prostate cancer
  • Drugs & Targets

    • FDA approves liquid biopsy NGS companion diagnostic test for multiple cancers and biomarkers
    • FDA issues guidance to enhance diversity in clinical trials, encourage inclusivity in medical product development
    • European Commission approves Opdivo + Yervoy with two cycles of chemotherapy for first-line treatment of metastatic NSCLC

Copyright (c) 2020 The Cancer Letter Inc.